Answers are grounded in this paper and cite their sources.
Objective: We conducted a systematic review of the literature from the PubMed database from January 1, 2010, to December 31, 2021. The search criteria were “(pityriasis versicolor OR tinea versicolor) AND treatment,” with the full text available and the English language required. This review focuses on the clinical evidence supporting the efficacy of antifungal and non-antifungal treatment for pityriasis versicolor. Background: Pityriasis versicolor is a chronic superficial mycosis caused by the Malassezia species. The condition is one of the most common infections worldwide, particularly in tropical climates. Although it is a superficial infection, recurrences are high due to the presence of Malassezia in the normal skin flora. Summary: Topical and oral antifungal treatments effectively reduce the recurrence, leading to a lasting clinical and mycological cure. In addition to antifungal therapies, non-antifungal treatments have shown efficacy in cases of recurrent pityriasis versicolor and could be used as maintenance or preventive therapy. Due to high recurrence rates, prophylactic treatment may be necessary.
No takes yet. Share an insight, caveat, or question.
Tirado‐Sánchez et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: